Health
Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei’s Position in IgA Nephropathy Treatment
CHELMSFORD, Mass. & TOKYO, November 04, 2025--2025 KDIGO Guideline suggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function
About this update from Asahi Kasei Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4999,"height":683,"url":"https://media.zenfs.com/en/business-wire.com/38142e08bd1e560ef3bb2b43af393fa8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.ALxqGaB2YJdSM8JxOZFFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/38142e08bd1e560ef3bb2b43af393fa8","width":960,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UZ8Z6tS0TIIjJl1t.qjtWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/38142e08bd1e560ef3bb2b43af393fa8","width":1200,"height":164}},"lazy":false},{"type":"text","content":"The final 2025 KDIGO Guideline suggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"CHELMSFORD, Mass. & TOKYO, November 04, 2025--(BUSINESS WIRE)--Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included in the Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).","length":440,"tagName":"p"},{"type":"text","content":"TARPEYO is a key product in Asahi Kasei’s pharmaceutical business, which the company has identified as a strategic growth area in its medium-term management plan. The inclusion of Nefecon in the KDIGO guidelines underscores its place in therapy and is expected to further support sustainable, long-term growth within Asahi Kasei’s healthcare portfolio.","length":352,"tagName":"p"},{"type":"text","content":"The updated KDIGO 2025 guideline aims to standardize care and improve outcomes by providing evidence-based recommendations related to IgAN diagnosis, prognosis and treatment.1 It is considered the global standard for nephrology practice and plays a central role in shaping treatment decisions for patients with IgAN.","length":316,"tagName":"p"},{"type":"text","content":"The KDIGO 2025 guideline suggests treatment with a 9-month course of Nefecon for patients at risk of progressive loss of ki...